AEON Biopharma (NASDAQ:AEON – Get Free Report) is projected to release its results on Friday, November 13th. Analysts expect the company to post earnings of ($0.10) per share for the quarter.
AEON Biopharma Price Performance
NASDAQ:AEON opened at $0.17 on Thursday. AEON Biopharma has a fifty-two week low of $0.13 and a fifty-two week high of $1.45. The stock’s 50-day moving average is $0.25 and its two-hundred day moving average is $0.64. The stock has a market cap of $8.55 million, a PE ratio of 0.95 and a beta of 0.68.
Analyst Upgrades and Downgrades
A number of brokerages recently commented on AEON. Laidlaw assumed coverage on shares of AEON Biopharma in a research report on Wednesday, September 9th. They set a “buy” rating and a $1.80 price objective on the stock. Lake Street Capital reiterated a “buy” rating and issued a $2.00 target price (up from $1.00) on shares of AEON Biopharma in a research report on Thursday, October 1st. Finally, HC Wainwright reiterated a “buy” rating and issued a $1.20 target price (down from $5.00) on shares of AEON Biopharma in a research report on Friday, August 14th. Three investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat.com, AEON Biopharma presently has a consensus rating of “Moderate Buy” and a consensus target price of $1.67.
View Our Latest Research Report on AEON
Insider Buying and Selling at AEON Biopharma
In other news, major shareholder Timothy P. Lynch purchased 1,150,000 shares of AEON Biopharma stock in a transaction dated Wednesday, August 19th. The stock was acquired at an average cost of $0.21 per share, for a total transaction of $241,500.00. Following the acquisition, the insider directly owned 6,500,000 shares in the company, valued at $1,365,000. This represents a 21.50% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 9.40% of the stock is owned by company insiders.
About AEON Biopharma
AEON Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on developing botulinum toxin-based therapies for therapeutic, rather than primarily aesthetic, applications. Its lead product candidate, ABP-450, is an investigational botulinum toxin type A complex being studied for the treatment of neurological and other medical conditions. AEON Biopharma has advanced ABP-450 in clinical development for conditions including chronic migraine and cervical dystonia, a disorder involving involuntary neck-muscle contractions.
Read More
- Five stocks we like better than AEON Biopharma
- Keeping AI Cool: AAON Rides the AI Heatwave to Record Growth
- AST SpaceMobile Has a New Rocket Plan, But Its Cash-Burn Problem Isn’t Going Away
- Powering Up the Moon: Redwire’s $40 Million NASA Award
- Can Constellation Energy’s Contracts Power a Stock Rebound?
Receive News & Ratings for AEON Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AEON Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
